KEYTRUDA QLEX (PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH)
KEYTRUDA QLEX (PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH) is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: KEYTRUDA QLEX; Generic name: PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH; Drug class: Programmed Death Receptor-1 Blocking Antibody [EPC].
| Brand name | KEYTRUDA QLEX |
|---|---|
| Generic name | PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH |
| Drug class | Programmed Death Receptor-1 Blocking Antibody [EPC] |
| Manufacturer | Merck Sharp & Dohme LLC |
| Used for | 1 INDICATIONS AND USAGE KEYTRUDA QLEX is a combination of pembrolizumab, a programmed death receptor-1 (PD-1)-blocking antibody, and berahyaluronidase alfa, an endoglycosidase, indicated: Melanoma for the treatment of adult patients with unresectable or metastatic melanoma. ( 1.1 ) for the adjuvant treatment of adult and pediatric patients 12 years and older with Stage IIB, IIC, or III melanoma following complete resection. ( 1.1 ) Non-Small Cell Lung Cancer (NSCLC) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) in combination with carboplatin and eit |
| Dosage | 2 DOSAGE AND ADMINISTRATION KEYTRUDA QLEX has different recommended dosage and administration than intravenous pembrolizumab. ( 2.2 ) KEYTRUDA QLEX is for subcutaneous use in the thigh or abdomen only. ( 2.2 ) Do not administer KEYTRUDA QLEX intravenously. ( 2.2 ) KEYTRUDA QLEX must be administered by a healthcare provider. ( 2.2 ) The recommended dose for adults and pediatric patients 12 years and older who weigh greater than 40 kg is: Every 3-week dosing (395 mg/4,800 units): Inject 2.4 mL sub |
| Active ingredient(s) | BERAHYALURONIDASE ALFA |
| Route | SUBCUTANEOUS |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=097d166f-b73b-41d3-9b37-7653cd2a0c41 |